bioRxiv · 10.64898/2026.09.23.753669
BI-TfR1 CapX rapidly transits the blood-brain barrier for efficient, low-dose gene delivery throughout the CNS
Abstract
Safe, efficient gene delivery throughout the CNS remains a central obstacle to treating genetic diseases of the brain and spinal cord. We describe BI-TfR1 CapX, a human transferrin receptor (TfR1)-binding AAV capsid that, after a low intravenous dose in adult humanized TFRC mice, transduced more than 80% of cortical and spinal neurons and ~60% of cortical astrocytes, with reduced distribution and expression in several peripheral tissues relative to AAV9. Unlike other engineered BBB-crossing capsids, CapX bound the CNS vasculature within minutes and a large fraction of its genomes reached parenchymal nuclei within 24 hours. Delivering a Prnp-targeted epigenetic silencer (Prnp-CHARM), CapX reduced brain Prnp mRNA by over 95% requiring 18-fold fewer vector genomes per brain cell than AAV-PHP.eB for 50% lowering. A CapX delivered dual-vector cytosine base editor installed a protein-truncating PRNP stop codon lowering brain prion protein by 80%. These properties make CapX an attractive vehicle for human CNS gene therapy.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Chan, K. Y., Lin, C.-Y., Huang, Q., Pacouret, S., Zheng, Q., Harvey, J. W., Brauer, P. P., Johnston, J., Serack, F., Davis, J. R., Kamath, N. G., Jereb, S., Sprague, D. A., Svanbergsson, A., Boucher, M., Minikel, E. V., Vallabh, S. M., Deverman, B. E.. 2026-09-29. BI-TfR1 CapX rapidly transits the blood-brain barrier for efficient, low-dose gene delivery throughout the CNS. https://doi.org/10.64898/2026.09.23.753669
Cite the original work for its findings. Save a collection to share your selection of sources.